Phytomedicine:丹芪通脉片复扰氧脂素以减轻急性心肌梗死

2022-04-25 紫菀款冬 MedSci原创

探究丹芪通脉片对急性心肌梗死的作用靶点和机制。

背景:急性心肌梗死(AMI)已成为全球发病率和死亡率增加的主要原因之一,AMI的缺血后炎症反应决定了缺血心脏修复和瘢痕形成的路径,丹芪通脉片(DQTT)临床常治疗AMI,其中丹酚酸(SA)三七皂苷(PNE)是DQTT主要活性物质,其大部分成分具有抗炎活性,特别是当它们在体内吸收时,然而DQTT在治疗AMI机制上对氧脂素代谢的调控机制尚未建立。

目的:探究DQTT对AMI的作用靶点和机制。

方法:通过网络药理学对主要成分SA和PNE进行靶点预测——花生四烯酸通路可能参与了DQTT对AMI的治疗作用。

建立H9C2心肌细胞的氧-糖剥夺/再氧模型验证花生四烯酸通路对环氧化酶(COX)和脂氧合酶(LOX)的调控作用。

动物实验中将大鼠随机分为7组:假手术组、AMI组、DQTT (65 mg/kg)、DQTT (130 mg/kg)、DQTT (260 mg/kg)、SA (22 mg/kg)、PNE (108 mg/kg),每组10只。采用LC/MS/ MS法对AMI大鼠进行DQTT氧磷脂靶向治疗。采用超高效液相色谱-三重四极杆质谱(UHPLC-QqQ/MS)检测系统测定AMI大鼠血浆38种氧磷脂的浓度。

使用细胞因子阵列,探究DQTT的抗炎作用显示为显著下调促炎细胞因子。

通过基因验证COX和LOX的表达和蛋白水平,验证恢复被干扰的花生四烯酸代谢是DQTT治疗AMI炎症的主要机制。

结果:细胞及动物实验发现通过DQTT治疗,受干扰的花生四烯酸代谢组部分恢复,抗炎脂蛋白显著升高,促炎脂蛋白降低。DQTT过花生四烯酸代谢、嘌呤代谢以及丙氨酸、天冬氨酸和谷氨酸代谢等多种代谢途径恢复AMI大鼠的稳态。细胞因子阵列分析发现,DQTT通过下调缺血心肌组织中COX-2ALOX5,使促炎细胞因子显著下调。

结论:DQTT可有效治疗急性心肌梗死,受干扰的花生四烯酸代谢组部分以剂量依赖性的方式得以恢复,抗炎代谢物显著升高,促炎脂质降低,证实DQTT对缺血组织损伤的抗炎作用。该研究表明,DQTT可能是一种很有前景的治疗AMI药物。

文献来源Zhi H, Zhang Z, Deng Y, etal. Restoring perturbed oxylipins with Danqi Tongmai Tablet attenuates acute myocardial infarction. Phytomedicine. 2021 Sep;90:153616.doi:10.1016/j.phymed.2021.153616

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1859252, encodeId=e9ac1859252af, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 15 08:47:11 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774050, encodeId=b4e61e7405089, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 05 03:47:11 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577888, encodeId=373a15e788824, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611555, encodeId=2239161155516, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2022-12-15 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1859252, encodeId=e9ac1859252af, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 15 08:47:11 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774050, encodeId=b4e61e7405089, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 05 03:47:11 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577888, encodeId=373a15e788824, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611555, encodeId=2239161155516, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2022-06-05 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1859252, encodeId=e9ac1859252af, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 15 08:47:11 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774050, encodeId=b4e61e7405089, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 05 03:47:11 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577888, encodeId=373a15e788824, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611555, encodeId=2239161155516, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1859252, encodeId=e9ac1859252af, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 15 08:47:11 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774050, encodeId=b4e61e7405089, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 05 03:47:11 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577888, encodeId=373a15e788824, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611555, encodeId=2239161155516, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 23 14:47:11 CST 2022, time=2022-04-23, status=1, ipAttribution=)]

相关资讯

Heart:流感疫苗与急性心肌梗死风险

接种流感疫苗对普通人群AMI的中等保护作用一致,主要在于一级预防。

JAMA:仅需2周,阿利珠单抗在目前治疗基础上明显改善急性心肌梗死患者斑块负荷!

冠状动脉斑块容易破裂并导致不良心脏事件的的特点是斑块负担大、脂质含量大、纤维帽薄。

EHJ-Acute CardioVascular Care:再论STEMI患者的“血脂悖论”,基于中国心血管疾病医疗质量改善项目的发现

近年来由于社会老龄化加剧,心血管病危险因素增多,急性心肌梗死(MI)发病率及死亡率不断攀升,造成了巨大的经济负担,因此控制冠状动脉性心脏病(CAD)患者死亡危险因素成为当下治疗热点。

NEJM:血管紧张素受体-脑啡肽酶抑制剂在急性心肌梗死治疗中的作用

在有症状的心力衰竭患者中,已发现沙库巴曲-缬沙坦比血管紧张素转换酶抑制剂能更有效地降低因心血管原因导致的住院和死亡风险。但一直缺乏比较这些药物对急性心肌梗死患者疗效的试验。

中药参元丹对急性心肌梗死作用机制

急性心肌梗死 (AMI) 对应于急性缺血性心肌坏死。它是一种严重的冠心病,其特点是冠状动脉供血急剧减少或中断,导致相应心肌严重长期缺血,最终导致心肌坏死。

营养不良小case?可使急性心梗PCI术后死亡风险升高6倍!

BMC Cardiovascular Disorders:营养状况对经皮冠状动脉介入治疗急性心肌梗死患者预后的影响